490 related articles for article (PubMed ID: 23494983)
1. A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans.
Schwab D; Portron A; Backholer Z; Lausecker B; Kawashima K
Clin Pharmacokinet; 2013 Jun; 52(6):463-73. PubMed ID: 23494983
[TBL] [Abstract][Full Text] [Related]
2. Metabolism and mass balance of SGLT2 inhibitor tofogliflozin following oral administration to humans.
Zell M; Husser C; Kuhlmann O; Schwab D; Uchimura T; Kemei T; Kawashima K; Yamane M; Pähler A
Xenobiotica; 2014 Apr; 44(4):369-78. PubMed ID: 24074237
[TBL] [Abstract][Full Text] [Related]
3. A double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [
Guerini E; Schadt S; Greig G; Haas R; Husser C; Zell M; Funk C; Hartung T; Gloge A; Mallalieu NL
Xenobiotica; 2017 Feb; 47(2):144-153. PubMed ID: 27123695
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Pharmacodynamics of Tofogliflozin (a Selective SGLT2 Inhibitor) in Healthy Male Subjects.
Kasahara-Ito N; Fukase H; Ogama Y; Saito T; Ohba Y; Shimada S; Takano Y; Ichihara T; Terao K; Nakamichi N; Kumagai Y; Ikeda S
Drug Res (Stuttg); 2017 Jun; 67(6):349-357. PubMed ID: 28427104
[TBL] [Abstract][Full Text] [Related]
5. An Innovative Approach to Characterize Clinical ADME and Pharmacokinetics of the Inhaled Drug Nemiralisib Using an Intravenous Microtracer Combined with an Inhaled Dose and an Oral Radiolabel Dose in Healthy Male Subjects.
Harrell AW; Wilson R; Man YL; Riddell K; Jarvis E; Young G; Chambers R; Crossman L; Georgiou A; Pereira A; Kenworthy D; Beaumont C; Marotti M; Wilkes D; Hessel EM; Fahy WA
Drug Metab Dispos; 2019 Dec; 47(12):1457-1468. PubMed ID: 31649125
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects.
Yang L; Li H; Li H; Bui A; Chang M; Liu X; Kasichayanula S; Griffen SC; Lacreta FP; Boulton DW
Clin Ther; 2013 Aug; 35(8):1211-1222.e2. PubMed ID: 23910664
[TBL] [Abstract][Full Text] [Related]
7. A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.
Kasahara N; Fukase H; Ohba Y; Saito T; Miyata K; Iida S; Takano Y; Ikeda S; Harigai M; Terao K
Drug Res (Stuttg); 2016 Feb; 66(2):74-81. PubMed ID: 26158794
[TBL] [Abstract][Full Text] [Related]
8. Effects of Child-Pugh B Cirrhosis on Pharmacokinetics of Tofogliflozin, a New Sodium-Glucose Co-Transporter (SGLT2) Inhibitor.
Yamada H; Ohira H; Ikegami F; Nakamura K; Takahashi A; Abe K; Inano A; Shimada S; Miyata K; Saito T; Ohba Y; Terao K; Ohnishi A
Drug Res (Stuttg); 2020 Sep; 70(9):401-409. PubMed ID: 32707593
[TBL] [Abstract][Full Text] [Related]
9. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
Friedrich C; Metzmann K; Rose P; Mattheus M; Pinnetti S; Woerle HJ
Clin Ther; 2013 Jan; 35(1):A33-42. PubMed ID: 23328275
[TBL] [Abstract][Full Text] [Related]
10. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
Nagata T; Fukazawa M; Honda K; Yata T; Kawai M; Yamane M; Murao N; Yamaguchi K; Kato M; Mitsui T; Suzuki Y; Ikeda S; Kawabe Y
Am J Physiol Endocrinol Metab; 2013 Feb; 304(4):E414-23. PubMed ID: 23249697
[TBL] [Abstract][Full Text] [Related]
11. Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus.
Hussey EK; Clark RV; Amin DM; Kipnes MS; O'Connor-Semmes RL; O'Driscoll EC; Leong J; Murray SC; Dobbins RL; Layko D; Nunez DJ
J Clin Pharmacol; 2010 Jun; 50(6):623-35. PubMed ID: 20056803
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of Velsecorat Using an Intravenous Microtracer Combined with an Inhaled Dose in Healthy Subjects.
Holmberg AA; Weidolf L; Necander S; Bold P; Sidhu S; Pelay-Gimeno M; de Ligt RAF; Verheij ER; Jauhiainen A; Psallidas I; Wählby Hamrén U; Prothon S
Drug Metab Dispos; 2022 Feb; 50(2):150-157. PubMed ID: 34853068
[TBL] [Abstract][Full Text] [Related]
13. Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans.
Mamidi RN; Cuyckens F; Chen J; Scheers E; Kalamaridis D; Lin R; Silva J; Sha S; Evans DC; Kelley MF; Devineni D; Johnson MD; Lim HK
Drug Metab Dispos; 2014 May; 42(5):903-16. PubMed ID: 24568888
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of an LC-MS/MS method for the determination of tofogliflozin in plasma and its application to a pharmacokinetic study in rats.
Kobuchi S; Matsuno M; Fukuda E; Ito Y; Sakaeda T
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1027():227-33. PubMed ID: 27304784
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.
Kasichayanula S; Liu X; Lacreta F; Griffen SC; Boulton DW
Clin Pharmacokinet; 2014 Jan; 53(1):17-27. PubMed ID: 24105299
[TBL] [Abstract][Full Text] [Related]
17. Dapagliflozin twice daily or once daily: effect on pharmacokinetics and urinary glucose excretion in healthy subjects.
Tang W; Reele S; Hamer-Maansson JE; Parikh S; de Bruin TW
Diabetes Obes Metab; 2015 Apr; 17(4):423-5. PubMed ID: 25511685
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Scheen AJ
Clin Pharmacokinet; 2015 Jul; 54(7):691-708. PubMed ID: 25805666
[TBL] [Abstract][Full Text] [Related]
19. Mass Balance and Absorption, Distribution, Metabolism, and Excretion Properties of Balcinrenone following Oral Administration in Combination with Intravenous Microtracer in Healthy Subjects.
Lindmark B; Li XQ; Bhattacharya C; Housler G; Heijer M; Bragg RA; Gränfors M; Pelay-Gimeno M; Vaes WHJ; Menakuru S; Pizzato PE; Ericsson H; Johansson S
Drug Metab Dispos; 2023 Aug; 51(8):995-1004. PubMed ID: 37407094
[TBL] [Abstract][Full Text] [Related]
20. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.
He YL; Sadler BM; Sabo R; Balez S; Wang Y; Campestrini J; Laurent A; Ligueros-Saylan M; Howard D
Clin Pharmacokinet; 2007; 46(9):787-802. PubMed ID: 17713976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
